Abstract
BackgroundBR101801 is an inhibitor of PI3K γ/δ and DNA-PK. It has received clinical approval from the U.S. FDA as an anticancer drug candidate, and phase 1a/1b is ongoing in the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have